Akero Therapeutics (AKRO) reported 96-week data in its trial of advanced MASH patients, and there seem really significant ...

The results of a phase 2b ENLIVEN trial of FGF21 analogue pegozafermin showed it was able to reduce scarring (fibrosis) in the liver of NASH patients at more than three times the rate of a placebo ...

Leerink Partners analyst Thomas Smith adjusted the price target for 89bio Inc . (NASDAQ:ETNB) to $37 from $34, while ...

due to NASH, a form of non-alcoholic fatty liver disease (NAFLD). In the 182-patient study, patients were treated with one of two doses of the FGF21 mimic or placebo - given as a once-weekly ...

Altered PPARA signaling in NASH contributes to messed-up fat processing and liver inflammation. Importantly, FGF19 and FGF21 are essential targets for drugs that regulate bile acids and energy in ...

周一，Leerink Partners分析师Thomas Smith将89bio Inc. (NASDAQ: ETNB )的目标价从34美元上调至37美元，同时重申对该股的"优于大市"评级。目前，该股交易价格为9.60美元，远低于分析师12美元至49美元的更广泛目标区间。根据 InvestingPro ...

Madrigal is likely to face competition as more NASH assets get approved, especially from the more efficacious FGF21 analogue drug class in more severe fibrotic NASH patient populations.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.